^
Association details:
| Biomarker: | IGH-CRLF2 fusion + JAK2 R683G |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | Fyarro (nanoparticle albumin-bound rapamycin) (mTORC1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Published date:
10/25/2012
Excerpt:
...we determined whether rapamycin conferred a survival advantage in Ph-like ALL xenografts…Rapamycin significantly prolonged survival compared with vehicle of both xenograft IV (Figure 5A, median survival 63 days vs 23 days, P < .01) and xenograft V (Figure 5B, median survival 91 days vs 58 days, P < .01)...
DOI:
https://doi.org/10.1182/blood-2012-03-415448
